SCHEMBL30952863

SCHEMBL30952863

Cn1c(=O)[nH]c2cccc(OCC(=O)OC(C)(C)C)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.47
▸ CRBN Q96SW2 1/20 0.47
▸ ADRB1 P08588 2/20 0.41
▸ ADRB3 P13945 1/20 0.41
▸ HPGD P15428 3/20 0.40
▸ PTPN1 P18031 3/20 0.40
▸ POLB P06746 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ EPHX2 P34913 1/20 0.37
▸ PSEN1 P49768 1/20 0.37
▸ PSEN2 P49810 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13844311 0.77 ADRB3 (0.40) ADRB1ADRB3POLBCYP2C19MEN1
SCHEMBL27265869 0.76 MAOB (0.51) PTPN1KDM4EALDH1A1MEN1KMT2A
SCHEMBL30939011 0.76 MAOB (0.54) PTPN1KDM4EALDH1A1PSEN1PSEN2
SCHEMBL22656552 0.73 POLB (0.50) DDB1CRBNHPGDPTPN1POLB
SCHEMBL22849479 0.73 EPHA2 (0.46) CYP2C19
SCHEMBL29502519 0.73 EPHA2 (0.46) CYP2C19
SCHEMBL29502291 0.73 EPHA2 (0.46) CYP2C19
SCHEMBL30225507 0.73 MAPT (0.47) HPGDPOLBMAPTNPSR1ALDH1A1
SCHEMBL11234999 0.73 ADRA2A (0.43) ADRB1ADRB3POLBMAPTKDM4E
SCHEMBL15128187 0.73 MAPT (0.47) HPGDPOLBMAPTNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630415-A1 TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN Captor Therapeutics S.A. (PL) 2025-10-15 — — EP disclosed
WO-2024121259-A1 TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-06-13 — — WO disclosed
Send feedback